Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1992 | 1 |
2011 | 1 |
2021 | 2 |
2022 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2.
Lancet. 2022.
PMID: 35691323
Clinical Trial.
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S; True North Study Group.
Sandborn WJ, et al.
N Engl J Med. 2021 Sep 30;385(14):1280-1291. doi: 10.1056/NEJMoa2033617.
N Engl J Med. 2021.
PMID: 34587385
Clinical Trial.
Item in Clipboard
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group.
Peyrin-Biroulet L, et al.
Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1.
Gastroenterology. 2023.
PMID: 37659673
Free article.
Clinical Trial.
Item in Clipboard
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group.
Peyrin-Biroulet L, et al.
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17.
Lancet Gastroenterol Hepatol. 2022.
PMID: 34798039
Free article.
Clinical Trial.
Item in Clipboard
Direct determination of the point mutation rate of a murine retrovirus.
Monk RJ, Malik FG, Stokesberry D, Evans LH.
Monk RJ, et al. Among authors: stokesberry d.
J Virol. 1992 Jun;66(6):3683-9. doi: 10.1128/JVI.66.6.3683-3689.1992.
J Virol. 1992.
PMID: 1316475
Free PMC article.
Item in Clipboard
Creating a diabetes chronic disease management program that works.
Baron A, Bernard E, Stokesberry D.
Baron A, et al. Among authors: stokesberry d.
Physician Exec. 2011 Jul-Aug;37(4):32-4, 36, 38-9.
Physician Exec. 2011.
PMID: 21827098
No abstract available.
Item in Clipboard
Cite
Cite